REGN Financial Facts

Total revenues: 1.22B
Loss from operations: 362.8M
See Full Income Statement

Total current liabilities: 961.19M
Facility lease obligations: 382.23M
See Full Balance Sheet

Regeneron Pharmaceuticals, Inc. (REGN ) Earnings

  |   Expand Research on REGN
Next EPS Date 8/3/26 *Est. EPS Growth Rate -100.0% *Last Qtr.
Average EPS % Beat Rate +20.0% Revenue Growth Rate -100.0% *Last Qtr.
Average % Move 1-Wk after EPS +3.4% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
4/30/26 Q126 N/A$9.14 N/A N/A$3.45B N/A N/A N/A
1/30/26 Q425 $11.44$10.52 +$0.92$3.88B$3.77B N/A Details
10/28/25 Q325 $11.83$9.64 +$2.19$3.75B$3.59B N/A Details
8/1/25 Q225 $12.89$8.50 +$4.39$3.68B$3.29B N/A Details
4/29/25 Q125 $8.22$8.48 -$0.26$3.03B$3.24B N/A Details
2/4/25 Q424 $12.07$11.27 +$0.80$3.79B$3.76B N/A Details
10/31/24 Q324 $12.46$11.72 +$0.74$3.72B$3.66B N/A Details
8/1/24 Q224 $11.56$10.61 +$0.95$3.55B$3.37B N/A Details